About: Salvage lenalidomide in four rare oncological diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Salvage lenalidomide in four rare oncological diseases Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	In rare disorders, there are often no standard therapy recommendations. Patients with refractory disease may require novel experimental approaches. Applied as second- up to fourth-line treatment, lenalidomide (10-25 mg perorally on days 1-21 in a 28-day cycle) was used in our cohort of four adult patients with aggressive, multisystem and relapsing diseases. Complete and long-lasting remissions (more than 1 year, no maintenance therapy) were achieved in patients with Langerhans cell histiocytosis (11 cycles, combination with dexamethasone and etoposide, consolidated by allogeneic blood stem cell transplant) and plasma-cell Castleman disease (15 cycles, monotherapy). Mixed response with complete disappearance of brain infiltrates was reached in Erdheim-Chester disease (6 cycles, monotherapy) and gastrointestinal bleeding was well controlled in multiple angiomatosis (9 cycles, combination with thalidomide). In rare disorders, there are often no standard therapy recommendations. Patients with refractory disease may require novel experimental approaches. Applied as second- up to fourth-line treatment, lenalidomide (10-25 mg perorally on days 1-21 in a 28-day cycle) was used in our cohort of four adult patients with aggressive, multisystem and relapsing diseases. Complete and long-lasting remissions (more than 1 year, no maintenance therapy) were achieved in patients with Langerhans cell histiocytosis (11 cycles, combination with dexamethasone and etoposide, consolidated by allogeneic blood stem cell transplant) and plasma-cell Castleman disease (15 cycles, monotherapy). Mixed response with complete disappearance of brain infiltrates was reached in Erdheim-Chester disease (6 cycles, monotherapy) and gastrointestinal bleeding was well controlled in multiple angiomatosis (9 cycles, combination with thalidomide). (en)
Title	Salvage lenalidomide in four rare oncological diseases Salvage lenalidomide in four rare oncological diseases (en)
skos:prefLabel	Salvage lenalidomide in four rare oncological diseases Salvage lenalidomide in four rare oncological diseases (en)
skos:notation	RIV/00216224:14110/13:00065660!RIV14-MZ0-14110___
http://linked.open...avai/predkladatel	Lékařská fakulta
http://linked.open...avai/riv/aktivita	I P
http://linked.open...avai/riv/aktivity	I, P(NT12215), P(NT13190)
http://linked.open...iv/cisloPeriodika	5
http://linked.open...vai/riv/dodaniDat	2014
http://linked.open...aciTvurceVysledku	Szturz, Petr Mayer, Jiří Krejčí, Marta Adam, Zdeněk
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykova univerzita / Lékařská fakulta
http://linked.open...dnocenehoVysledku	103921
http://linked.open...ai/riv/idVysledku	RIV/00216224:14110/13:00065660
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Langerhans cell histiocytosis; Erdheim-Chester disease; angiomatosis; Castleman disease (en)
http://linked.open.../riv/klicoveSlovo	Erdheim-Chester disease Langerhans cell histiocytosis angiomatosis Castleman disease
http://linked.open...odStatuVydavatele	IT - Italská republika
http://linked.open...ontrolniKodProRIV	[3A458B6AC2C6]
http://linked.open...i/riv/nazevZdroje	Tumori
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	4 (xsd:int)
http://linked.open...cetTvurcuVysledku	8 (xsd:int)
http://linked.open...vavai/riv/projekt	Molecular signature of centrosome abnormalities and their clinical impact for patients with multiple myeloma Rationalization of therapy of multiple myeloma
http://linked.open...UplatneniVysledku	2013
http://linked.open...v/svazekPeriodika	99
http://linked.open...iv/tvurceVysledku	Adam, Zdeněk Krejčí, Marta Mayer, Jiří Moulis, Mojmír Szturz, Petr Křen, Leoš Koukalova, Renata Rehak, Zdenek
issn	0300-8916
number of pages	6 (xsd:int)
http://bibframe.org/vocab/doi	10.1700/1377.15326
http://localhost/t...ganizacniJednotka	14110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 24 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software